Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Total Current Liabilities of $209.0 million for Q1 2026, up 8.85% year-over-year from $192.0 million in Q1 2025, and down 9.52% quarter-over-quarter from $231.0 million in Q4 2025.
Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2026) Analysis & Trends
Arcus Biosciences' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $209.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 8.85% year-over-year to $209.0 million; the TTM figure through Mar 2026 stood at $209.0 million (up 8.85% YoY), while the FY2025 annual figure was $231.0 million, up 2.21% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $209.0 million, down from $231.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $235.0 million in Q3 2025, with the low at $4.0 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $199.0 million (2024), against an average of $187.3 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 97.52% in 2023, then surged 5000.0% in 2024.
- Arcus Biosciences' Total Current Liabilities stood at $193.0 million in 2022, then declined by 4.66% to $184.0 million in 2023, then grew by 22.83% to $226.0 million in 2024, then rose by 2.21% to $231.0 million in 2025, then fell by 9.52% to $209.0 million in 2026.
- Business Quant data shows RCUS's Total Current Liabilities at $209.0 million in Q1 2026, $231.0 million in Q4 2025, and $235.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 198.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 198.00 Mn |
| Mar 31, 2026 | 209.00 Mn |
| Dec 31, 2025 | 231.00 Mn |
| Sep 30, 2025 | 235.00 Mn |
| Jun 30, 2025 | 210.00 Mn |
| Mar 31, 2025 | 192.00 Mn |
| Dec 31, 2024 | 226.00 Mn |
| Sep 30, 2024 | 215.00 Mn |
| Jun 30, 2024 | 199.00 Mn |
| Mar 31, 2024 | 204.00 Mn |
| Dec 31, 2023 | 184.00 Mn |
| Sep 30, 2023 | 200.00 Mn |
| Jun 30, 2023 | 180.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 193.00 Mn |
| Sep 30, 2022 | 177.18 Mn |
| Jun 30, 2022 | 164.02 Mn |
| Mar 31, 2022 | 161.25 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 142.87 Mn |